13 related news articles for Metastasis Biology and Therapeutics

One of the most exciting developments in ovarian cancer treatment in decades will form the basis of a new two-year research project at Hudson Institute, thanks to the generosity of the CanToo Foundation.…  Read more

A diagnosis of ovarian cancer carries a dual threat – the disease itself and the danger of the cancer spreading – but the latest research from Hudson Institute has uncovered a crucial factor, leader cells, that are crucial to both.…  Read more

There are few parts of the Australian community that remain untouched by ovarian cancer. The team at Spotlight Group Holdings, one of the nation’s largest retail organisations, is supporting Hudson Institute’s work to help find a cure and better early diagnostics for the deadly disease.…  Read more

Jessica Clark calls herself the luckiest unlucky person in the world – but she still wants to know why she got ovarian cancer at such a young age.…  Read more

Exciting new treatments for unmet medical needs including ovarian cancer have been awarded significant funding from Australia’s national biotechnology incubator, CUREator.…  Read more

For the month of ‘frocktober’ ovarian cancer researchers, Dr Maree Bilandzic and Dr Amy Wilson swapped their white lab coats for colourful frocks as part of the Frocktober campaign to raise funds and awareness for ovarian cancer research.…  Read more

Highly mobile, invasive ovarian cancer cells called ‘leader cells’ have been discovered as the cells that lead the attack on healthy tissue.…  Read more

Dr Bilandzic, an ovarian cancer researcher, has been awarded $700,000 for research into deadly ovarian cancer cells called ‘leader cells’, which can survive and even thrive in response to cancer treatment. …  Read more

Two Hudson Institute researchers, Dr Jun Yang and Dr Maree Bilandzic have been successful in the 2019 IMPACT Philanthropy program, from Perpetual, which are awarded to organisations based on their strategy, outcomes, capability and leaderships.…  Read more

Ovarian cancer is responsible for more deaths than any other gynaecological disease, yet it’s known as the ‘silent killer’, due to an absence of symptoms and a devastatingly low survival rate of less than 50 per cent. Our leading ovarian cancer researchers are progressing solutions to help these women – thanks to support from the…  Read more

Ovarian cancer research leaders from across Australia met at Hudson Institute of Medical Research on Thursday, 15 November, for a new research symposium focused on progressing solutions to the disease.…  Read more

The Active Ratio Test represents an exciting step forward in innovative ovarian cancer research. Should it be successful, a test as simple as taking a swab or blood sample will result in the early detection of ovarian cancer in women who otherwise exhibit no symptoms. Vague and misleading symptoms, combined with the need for invasive…  Read more

Hudson Institute’s brightest scientific minds and most promising discoveries will be progressed, thanks to support from a leading philanthropist, Mr Peter Fielding and the Fielding Foundation. The 2018 Fielding Innovation Award has been awarded to Dr Maree Bilandzic to develop more effective treatments for women with ovarian cancer. The 2018 Fielding Foundation Fellowship has been…  Read more